Perth headquartered biotechnology company Stirling Products Ltd has finalised a $1.3 million placement to US institutional investor, Indus Capital Partners, LLC, to fund the further development of R-salbutamol as a growth agent and in obesity applications
22/05/2006 - 10:53
Stirling finalises $1.3m placement to fund product development
22/05/2006 - 10:53
